Internal Medicine, Rheumatology · Lake Charles, LA
NPI
1174605646
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1727 Imperial Blvd Bldg 1b
Lake Charles, LA, 70605
Phone (337) 312-8617
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
100,431 services
Medicare patients, 2024
890
Average age 73
Drug cost, 2024
$7.3M
7,066 prescriptions
Company payments, 2025
$7,678
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Enrique A Mendez was code J1306 (injection, inclisiran, 1 mg), 15,052 times for 29 patients. In total Enrique A Mendez billed 100,431 services in 68 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1306 Injection, inclisiran, 1 mg | Office | 15,052 | 29 | $9.48 | $143K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 8,850 | 11 | $8.96 | $79K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 3,484 | 43 | $0.10 | $352 |
| J0897 Injection, denosumab, 1 mg | Office | 3,300 | 42 | $19.27 | $64K |
| 99214 Office E&M - Established | Office | 2,737 | 482 | $84.13 | $230K |
| 99427 Chronic, Principal, and Transitional Care Management | Office | 346 | 160 | $32.45 | $11K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 332 | 173 | $40.50 | $13K |
| 96372 Injection Administration | Office | 257 | 116 | $9.28 | $2,384 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 206 | 39 | $12.24 | $2,522 |
| 96365 Intravenous Infusion, Hydration | Office | 140 | 26 | $39.30 | $5,502 |
| 93306 Echocardiography (TTE/TEE) | Office | 139 | 138 | $74.47 | $10K |
| 93880 Duplex Scan - Extracranial Arteries | Office | 106 | 106 | $96.24 | $10K |
| 99231 Hospital E&M - Subsequent | Facility | 91 | 51 | $36.18 | $3,292 |
| 96413 Chemotherapy Administration | Office | 68 | 12 | $86.08 | $5,853 |
| 99205 Office E&M - New | Office | 48 | 48 | $133.29 | $6,398 |
By year: 2022 $1.4M for 104,739 services; 2023 $1.5M for 125,415 services; 2024 $1.3M for 100,431 services.
Medicare prescription drug claims, 2024
In 2024, the drug Enrique A Mendez prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 2,414 prescriptions and refills. In total Enrique A Mendez wrote 7,066 Medicare prescriptions that cost $7.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 2,414 | 2,414 | 353 | $50K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 516 | 516 | 82 | $14K |
| Gabapentin Generic | 445 | 697 | 104 | $4,541 |
| Oxycodone Hcl Generic | 401 | 401 | 70 | $6,046 |
| Prednisone Generic | 327 | 556 | 84 | $1,546 |
| Pregabalin Generic | 286 | 328 | 55 | $3,281 |
| Hydroxychloroquine Sulfate Generic | 284 | 486 | 73 | $8,512 |
| Tramadol Hcl Generic | 220 | 220 | 44 | $1,539 |
| Methotrexate Methotrexate Sodium | 199 | 390 | 53 | $3,845 |
| Hydromorphone Hcl Generic | 98 | 98 | 21 | $1,373 |
| Baclofen Generic | 91 | 118 | 25 | $1,012 |
| Tizanidine Hcl Generic | 80 | 124 | 24 | $749 |
| Rinvoq Upadacitinib | 78 | 80 | 15 | $509K |
| Trazodone Hcl Generic | 57 | 73 | 13 | $212 |
| Celecoxib Generic | 56 | 120 | 17 | $881 |
Brand drugs: - claims; generic drugs: 6,440 claims; opioid claims: 3,775.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Enrique A Mendez $7,678 ($7,678 in general payments such as food, travel and fees) from 22 companies. The largest payer was ANI Pharmaceuticals, Inc. with $4,795.
| Company | Payments | Amount |
|---|---|---|
| ANI Pharmaceuticals, Inc. ANIP | 24 | $4,795 |
| Abbvie Inc. ABBV | 41 | $791 |
| Amgen Inc. AMGN | 41 | $623 |
| Mallinckrodt Hospital Products Inc. | 19 | $488 |
| Janssen Biotech, Inc. JNJ | 14 | $329 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $214 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $91.25 |
| Genzyme Corporation SNY | 3 | $87.04 |
| GlaxoSmithKline, LLC. GSK | 4 | $64.81 |
| Aurinia Pharma U.S., Inc. AUPH | 3 | $54.61 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.